Prenatal exposure to valproate has been associated with an elevated risk (10%) for a broad range of congenital malformations including neural tube defects, as well as adverse neurodevelopmental sequelae, including lower IQ and developmental delays [...]
While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]
This is the first installment of a new feature on our website: ESSENTIAL READS This is a kind of shortcut which allows you to find the most relevant reviews and articles in reproductive psychiatry. [...]
Prozac (fluoxetine) was the first SSRI or selective serotonin reuptake inhibitor. Since its release in 1988, we have been gathering data on the reproductive safety of fluoxetine and other SSRIs. Over the last 32 years, [...]
Given the number of younger women using atypical antipsychotic medications, there is an urgent need for more accurate data regarding the reproductive safety of these medications. One important question is whether these newer antipsychotic [...]
For women taking antidepressants, how do we decide whether or not they should maintain their medication during pregnancy? Based on our previous research and clinical experiences, we know that many women who discontinue antidepressant [...]
Last week, I met with a woman who was planning pregnancy. She had a long history of generalized anxiety disorder and panic disorder and had done very well over the past 10 years on [...]
From the OptumLabs Data Warehouse, researchers identified 226,932 singleton deliveries. Cases of antidepressant exposure were defined as pregnancies with prescription claims for antidepressants submitted between the last menstrual period and 35 weeks’ gestation. To [...]
While we have data to support the use of antidepressants, including the selective serotonin reuptake inhibitors (SSRIs) and the serotonin norepinephrine reuptake inhibitors (SNRIs), during pregnancy, most studies have focused on risk of congenital [...]
In 2015, the U.S. Food and Drug Administration (FDA) proposed major revisions to prescription drug labeling -- the Pregnancy and Lactation Labeling Rule or PLLR -- in order to provide more accurate and helpful [...]
